Saudi Arabia LCGPA signs localization/knowledge-transfer agreements for biologic medicines (adalimumab, etanercept) and orthopedic implants at Global Health Exhibition 2025

Mechanism

LCGPA's standing "Localization of Industry & Knowledge Transfer" (LIKT) contracting method — the same mechanism behind the December 2025 polymer street-lighting-pole and Mandatory List filings already in the register — was used at the Global Health Exhibition 2025 (Riyadh) to sign five agreements covering three product categories: etanercept (biologic, manufacture + tech transfer), orthopedic trauma/fracture implants, and adalimumab (biologic), the latter signed as two separate agreements — one each with Boston Oncology Arabia and Tabuk Pharmaceuticals. The ceremony was held under Minister of Industry and Mineral Resources / LCGPA Chairman Bandar Alkhorayef and LCGPA CEO Abdulrahman Al-Samari.

Once qualifying domestic production is established, LCGPA's standard practice (confirmed in the December 2025 Mandatory List filing) is to add the localized product to the binding Mandatory List, which would require Saudi government entities, SOEs, and their sub-contractors to source these biologics and implants exclusively from the qualifying domestic manufacturers — displacing imported biosimilars/implants from incumbent foreign suppliers (e.g. AbbVie for adalimumab, Amgen/Pfizer for etanercept originator/biosimilar lines).

Severity is set at 2 (low-moderate): the disclosed SAR 1.2bn/10-year GDP impact and ~500 jobs figure (from Boston Oncology's own release, covering only its share of the agreements) is a real but modest quantum relative to the SAR 500bn+ annual government procurement envelope covered by the wider Mandatory List regime — this is a narrow, product-specific expansion of that regime rather than a standalone large-scale measure.

Downstream implications

• Foreign biologics suppliers (AbbVie's Humira/adalimumab originator and

biosimilar competitors, Amgen/Pfizer etanercept lines) and orthopedic implant importers face eventual Mandatory List exclusion from Saudi government and SOE healthcare procurement once local production from Boston Oncology, Tabuk Pharmaceuticals, and the other named counterparties reaches qualifying volumes.

• Confirms the recurring LIKT product-localization pattern (see also the

2025-12-01 polymer lighting-pole filing) as an ongoing, lower-severity filing category distinct from periodic Mandatory List batch expansions.

• Reinforces Saudi Arabia's Vision 2030 target of localizing 40% of the

pharmaceuticals market by 2030.

Open questions

• Exact roles of Rameem Medical, Bio Vision, Sudair Pharma, and Almana

Company (named by GTA but not by the SPA primary source) — likely cover the orthopedic-implant agreement and/or sub-contracting roles within the Boston Oncology / Tabuk Pharmaceuticals deals; not resolved by available public sources.

• Date of eventual Mandatory List addition for these products (and the

resulting binding-sourcing effective date) not yet announced.